Revolutionizing oral mucositis treatment: Antibacterial light-activated therapy in future protocols

Source: www.dentistryiq.com Author: Nina Garlo-Melkas, MSc Recent research suggests that antibacterial dual-light therapy may be an effective method to manage the symptoms of oral mucositis. Here’s what you need to know about this promising treatment. Oral mucositis, an inflammation of the oral mucosa, often occurs in association with cancer treatments, particularly radiation and chemotherapy. It manifests as severe pain, redness, and swelling in the mouth, potentially impacting the success of cancer therapy. To date, no existing medication has effectively prevented the development of mucositis. But recent research suggests that antibacterial dual-light therapy may be an effective method to manage the symptoms of this condition. Traditional approaches to treating oral mucositis include preventive measures such as maintaining good oral hygiene and using ice therapy during chemotherapy. If bacterial infection is present, doctors may consider the use of antibiotics. Corticosteroids are also a treatment option to alleviate pain and the inflammatory response associated with mucositis. However, corticosteroid use poses risks as it can suppress the immune system, making cancer patients more susceptible to infections.1,2 Ongoing research explores novel methods for preventing and treating oral mucositis. Mitochondria-stimulating red-light therapy has proven to be very effective in treating oral mucositis, particularly as a preventive measure. Although light therapy is estimated to be the most effective treatment modality, its widespread implementation faces challenges such as availability and practical issues.3 The latest studies investigate antibacterial treatments to preventively address oral mucosal ulcers originating from mucositis, aiming to mitigate the adverse effects of aggressive cancer treatments. In [...]

Food preservative may halt tumor growth

Source: www.foodproductdesign.com The common food preservative nisin may stop or slow squamous cell head and neck cancers, according to a new study published in the journal Cancer Medicine. The findings may accelerate new cancer therapies since the U.S. Food and Drug Administration (FDA) and the World Health Organization (WHO) approved nisin as safe for human consumption decades ago. Oral cancer is a leading cause of death worldwide, and oral squamous cell carcinoma accounts for more than 90% of oral cancers. However, survival rates for oral cancer haven't improved in decades, according to the study. Yvonne Kapila, the study's principal investigator and professor at the University of Michigan School of Dentistry, said antibacterial agents like nisin alter cell properties in bacteria to render it harmless. However, it's only recently that scientists began looking to antibacterial agents like nisin to see if they altered properties in other types of cells, such as cancer cells or cells in tumors. "The poor 5-year survival rates for oral cancer underscore the need to find new therapies for oral cancer," she said. "The use of small antibacterial agents, like nisin, to treat cancer is a new approach that holds great promise. Nisin is a perfect example of this potential because it has been used safely in humans for many years, and now the laboratory studies support its anti-tumor potential." The study, which looked at the use of antimicrobials to fight cancerous tumors, suggests nisin, in part, slows cell proliferation or causes cell death through the activation [...]

2012-11-01T15:17:35-07:00November, 2012|Oral Cancer News|
Go to Top